login
  Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 




Featured Highlights
41 - 60 of 142   Items

Boston Scientific announces its support activities for Awareness of Colorectal Cancer Month

Thursday, 14 Mar 2013
Boston Scientific announced it is supporting Colorectal Cancer Awareness Month with a range of awareness-raising activities throughout March. Boston Scientific announces its support activities for Awareness of Colorectal Cancer Month
Nordion launches updated TheraSphere website for liver cancer physicians, patients and carers

Nordion launches updated TheraSphere website for liver cancer physicians, patients and carers

Thursday, 07 Mar 2013
TheraSphere.com, the new TheraSphere website, provides resources and targeted information about radioembolization therapy and is available as an iPad app, according to a company release. Nordion launches updated TheraSphere website for liver cancer physicians, patients and carers

Study data suggests 95% cure rate for men with prostate cancer using high intensity focused ultrasound

Thursday, 07 Mar 2013
Prostate patients, according to data announced by the Diagnostic Center for Disease, Florida, USA, said that there could be a 95% cure rate when biopsy is used in conjunction with 3 telsa magnetic resonance imaging spectroscopy. Study data suggests 95% cure rate for men with prostate cancer using high intensity focused ultrasound

Surefire Medical infusion system can prevent embolics entering non-target vessels for the treatment of liver cancer

Thursday, 07 Mar 2013
According to Surefire Medical and a study published in CardioVascular and Interventional Radiology, the Surefire infusion system can prevent embolics, such as those used for treating liver cancer, entering distal non-target vessels. Surefire Medical infusion system can prevent embolics entering non-target vessels for the treatment of liver cancer
TACE procedure in Japan and Korea was favourable for overall survival in hepatocellular carcinoma patients

TACE procedure in Japan and Korea was favourable for overall survival in hepatocellular carcinoma patients

Monday, 04 Mar 2013
According to results of a study published in the Journal of Vascular and Interventional Radiology, a transcatheter arterial chemoembolization (TACE) procedure using an emulsion of lipidol, an anthracycline agent and gelatin sponge particles, in Asia, was favourable for patient outcomes compared with Western TACE. TACE procedure in Japan and Korea was favourable for overall survival in hepatocellular carcinoma patients
Coding Strategies offers new radiology and oncology HCPCS resource guides

Coding Strategies offers new radiology and oncology HCPCS resource guides

Monday, 04 Mar 2013
According to a company release, designed for quick and easy reference, Coding Strategies has launched two new HCPCS resource guides for radiology and oncology. Coding Strategies offers new radiology and oncology HCPCS resource guides
Lower rates of post-embolization syndrome and fatigue with smaller drug-eluting beads for hepatocellular carcinoma

Lower rates of post-embolization syndrome and fatigue with smaller drug-eluting beads for hepatocellular carcinoma

Friday, 22 Feb 2013
In a study published in the Journal of Vascular and Interventional Radiology, Siddharth A Padia and colleagues compared 100–300µm and 300–500µm drug-eluting beads for the treatment of hepatocellular carcinoma patients. Lower rates of post-embolization syndrome and fatigue with smaller drug-eluting beads for hepatocellular carcinoma
Benefits of computed tomography outweigh cancer risks in young adults

Benefits of computed tomography outweigh cancer risks in young adults

Thursday, 21 Feb 2013
A study, jointly led by Robert L Zondervan and Susanna Lee, has said that young adults who undergo computed tomography (CT) are more at risk from underlying medical conditions rather than radiation-induced cancer from CT. Benefits of computed tomography outweigh cancer risks in young adults
Varian Medical Systems receives FDA 510(k) clearance for the Edge radiosurgery suite

Varian Medical Systems receives FDA 510(k) clearance for the Edge radiosurgery suite

Wednesday, 30 Jan 2013
Edge radiosurgery suite, a new dedicated system for performing advanced radiosurgery using real-time tumour tracking and motion management technologies, has been granted FDA approval. Varian Medical Systems receives FDA 510(k) clearance for the Edge radiosurgery suite
Interventional treatment with radioactive beads could help colon cancer patients live longer

Interventional treatment with radioactive beads could help colon cancer patients live longer

Monday, 28 Jan 2013
In a presentation at ISET, data from a study using Y-90 radioactive beads for the treatment of liver-dominant metastases from colorectal cancer showed that patients may live longer than with chemotherapy alone. Interventional treatment with radioactive beads could help colon cancer patients live longer
Upgraded version of Accu2i pMTA microwave ablation device gets FDA clearance

Upgraded version of Accu2i pMTA microwave ablation device gets FDA clearance

Tuesday, 11 Dec 2012
Improvements of the new device include a refined optically clear moulded handle and improved connection cartridge. Upgraded version of Accu2i pMTA microwave ablation device gets FDA clearance
FDA clears FlightPlan for Liver imaging tool for liver embolization procedures

FDA clears FlightPlan for Liver imaging tool for liver embolization procedures

Monday, 26 Nov 2012
The FlightPlan for Liver tool (GE Healthcare), developed by physicians and engineers, helps interventionalists plan their liver embolization procedures in a simpler manner. FDA clears FlightPlan for Liver imaging tool for liver embolization procedures
CyberKnife VSI System now in India

CyberKnife VSI System now in India

Thursday, 22 Nov 2012
Accuray Incorporated has announced that Medanta – The Medicity Cancer Institute, and the Roentgen-BLK Super Speciality Hospital both recently acquired and started treating patients with the CyberKnife VSI System, marking it the first-in-country CyberKnife VSI System in India. CyberKnife VSI System now in India
Thermedical receives FDA 510(k) clearance for new ablation system

Thermedical receives FDA 510(k) clearance for new ablation system

Wednesday, 07 Nov 2012
The new system, sponsored by the Massachussets Life Sciences Centre, utilises radiofrequency for the treatment of large tumours, including liver cancer. Thermedical receives FDA 510(k) clearance for new ablation system
Delcath receives regulatory approval for the Generation Two Hepatic Chemosat Delivery system in Australia

Delcath receives regulatory approval for the Generation Two Hepatic Chemosat Delivery system in Australia

Tuesday, 06 Nov 2012
The approval allows Delcath to market and sell the system used to treat unresectable metastatic melanoma in the liver in Australia. Delcath receives regulatory approval for the Generation Two Hepatic Chemosat Delivery system in Australia
Sirtex Medical launches SIR-Spheres microspheres in Latin America

Sirtex Medical launches SIR-Spheres microspheres in Latin America

Monday, 15 Oct 2012
The first treatment with the SIR-Spheres Microspheres for inoperable liver tumours was carried out at Hospital Italiano de Buenos Aires in Argentina. Sirtex Medical launches SIR-Spheres microspheres in Latin America

FDA clears Surefire Medical Angiographic Catheters

Monday, 15 Oct 2012
According to a company release, the Surefire Angiographic Catheters are designed to provide interventional radiologists with greater flexibility and a high level of trackability when performing infusion procedures. FDA clears Surefire Medical Angiographic Catheters

Philips and Biocompatibles team-up to advance image guided transarterial embolizations in interventional oncology

Wednesday, 19 Sep 2012
At CIRSE 2012, Philips and Biocompatibles announced a collaboration to advance the use of image guidance to control the delivery of beads during the arterial embolization of hypervascularised tumours. Philips and Biocompatibles team-up to advance image guided transarterial embolizations in interventional oncology
Is there a difference in radioembolization outcomes between glass and resin microspheres?

Is there a difference in radioembolization outcomes between glass and resin microspheres?

Thursday, 06 Sep 2012
Is one device more effective than the other, with respect to radioembolization for hepatocellular carcinoma with or without portal vein thrombosis, metastatic colorectal cancer and neuroendocrine tumours? Examining the medical literature, the answer is “no”, Robert Lewandowski, Chicago, USA, said. Is there a difference in radioembolization outcomes between glass and resin microspheres?
Surefire Infusion System for embolization procedures receives CE mark approval

Surefire Infusion System for embolization procedures receives CE mark approval

Wednesday, 05 Sep 2012
In a retrospective study of 29 patients, infusion of therapeutic agent with the Surefire Infusion System showed no angiographic evidence of reflux and no clinical evidence of non-target embolization. Surefire Infusion System for embolization procedures receives CE mark approval
Found: 142   Displaying: 41-60
Results: 3 4 5 6 7 Next Go to:

Related Section


Clinical Trials
Interventional Oncology News
Interventional Oncology Supplement
Key Opinion Leaders discuss the role of Biocompatible's DC Bead at CIRSE and ILCA
IR Views
Literature
Oncology Useful Links

Related Feeds


Most popular


OVER analysis: Endoleak does not predict reduced long-term survival but negatively impacts sac regression
Wednesday, 18 Jun 2014
An analysis of the OVER trial presented at the Society for Vascular Surgery Vascular Annual Meeting (SVS, 5–7 June, Boston, USA) shows that the development of endoleaks were common in patients ... OVER analysis: Endoleak does not predict reduced long-term survival but negatively impacts sac regression

Medtronic to acquire Covidien for US$42.9 billion in cash and stock
Monday, 16 Jun 2014
The acquistion creates a medical technology and services company with a comprehensive product portfolio and broad global reach. Medtronic to acquire Covidien for US$42.9 billion in cash and stock

FDA advisory panel unanimously recommends approval for Lutonix DCB
Friday, 13 Jun 2014
Lutonix DCB is one step closer to becoming the first US FDA-approved drug-coated balloon for the treatment of patients with femoropopliteal occlusive disease. FDA advisory panel unanimously recommends approval for Lutonix DCB

Features


The 11th Scientific Meeting of the Chinese Society of Interventional Radiology successfully held in Changsha
Tuesday, 08 Jul 2014
The 11th Scientific Meeting of the Chinese Society of Interventional Radiology (2014 CSIR) was held from 11–15 June 2014 in Changsha, Hunan Province, China. The Chinese Society of Interventional R... The 11th Scientific Meeting of the Chinese Society of Interventional Radiology successfully held in Changsha

Pressure-directed embolotherapy using antireflux devices to perform liver directed regional therapy
Tuesday, 08 Jul 2014
Unintended non-target delivery of embolic agents into any of the various hepaticoentric arteries that course from an intrahepatic artery to implant into an extra hepatic organ such as the stomach or ... Pressure-directed embolotherapy using antireflux devices to perform liver directed regional therapy

Profiles


Bien Soo Tan
Friday, 16 May 2014
Bien Soo Tan, senior consultant, Department of Diagnostic Radiology, Singapore General Hospital, S... Bien Soo Tan

James B Spies
Friday, 16 May 2014
The evolution of embolization over the past decade has been remarkable and it has fundamentally ... James B Spies

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions